Lumos Pharma Presents Updated Phase 2 OraGrowtH Data Demonstrating Sustained Growth On Oral LUM-201 To 24 Months In PGHD And Correlation Of Growth To LUM-201's Unique Pulsatile Mechanism Of Action At ESPE 2024
Lumos Pharma Presents Updated Phase 2 OraGrowtH Data Demonstrating Sustained Growth On Oral LUM-201 To 24 Months In PGHD And Correlation Of Growth To LUM-201's Unique Pulsatile Mechanism Of Action At ESPE 2024
lumos pharma展示了更新的第二階段OraGrowtH數據，證明在PGHD中，口服LUm-201持續生長達到24個月，並且生長與LUm-201獨特的脈動作用機制相關，展示於2024年ESPE會議。
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.
lumos pharma公司（納斯達克：LUMO）是一家臨床階段的生物製藥公司，專注於治療稀有疾病，宣佈在2024年11月16日至18日於英國利物浦舉行的第62屆歐洲兒科內分泌學會年會上，口頭展示了來自其第二階段OraGrowtH210和OraGrowtH212臨床試驗的數據的新分析。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間